IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden · Delayed Price · Currency is SEK 1.620
+0.046 (2.92%)
Aug 13, 2026, 5:29 PM CET
IRLAB Therapeutics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 50.79 | 81.86 | 66.92 | 111.31 | 252.78 | 401.9 |
Cash & Short-Term Investments | 50.79 | 81.86 | 66.92 | 111.31 | 252.78 | 401.9 |
Cash Growth | -42.68% | 22.33% | -39.88% | -55.96% | -37.10% | 45.08% |
Accounts Receivable | - | - | - | - | 3.32 | 4.47 |
Other Receivables | - | 3.32 | 6.39 | 9.17 | 6.6 | 6.27 |
Total Trade Receivables | - | 3.32 | 6.39 | 9.17 | 9.92 | 10.74 |
Other Current Assets | - | 3.29 | 6.25 | 3.11 | 5.99 | 8.8 |
Total Current Assets | 83.74 | 88.47 | 79.56 | 123.59 | 268.68 | 421.44 |
Net Property, Plant & Equipment | 4.43 | 5.47 | 9.79 | 6.67 | 8.01 | 8.35 |
Other Intangible Assets | 46.86 | 46.86 | 46.86 | 46.86 | 46.86 | 42.66 |
Total Assets | 135.03 | 140.8 | 136.21 | 177.12 | 323.56 | 472.45 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | - | 5.29 | 9.94 | 10.52 | 10.03 | 12.3 |
Accrued Expenses | - | 71.46 | 28.85 | 14.91 | 13.44 | 48.42 |
Current Portion of Long-Term Debt | 24.41 | 26.42 | 53.47 | - | - | - |
Current Portion of Leases | 2.67 | 3.54 | 3.42 | 2.94 | 3.6 | 3.03 |
Other Current Liabilities | 68.11 | 3.39 | 4.37 | 8.35 | 5.28 | 5.65 |
Total Current Liabilities | 95.19 | 110.09 | 100.04 | 36.73 | 32.34 | 69.4 |
Long-Term Debt | - | - | - | 24.51 | - | - |
Long-Term Leases | - | - | 3.54 | 0.12 | 0.38 | 3.57 |
Total Long-Term Liabilities | - | - | 3.54 | 24.63 | 0.38 | 3.57 |
Total Liabilities | 95.19 | 110.09 | 103.58 | 61.36 | 32.72 | 72.97 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1.7 | 1.7 | 1.04 | 1.04 | 1.04 | 1.04 |
Additional Paid-in Capital | 800.41 | 800.41 | 690.21 | 690.21 | 690.21 | 685.45 |
Retained Earnings | -762.27 | -771.39 | -658.61 | -575.48 | -400.41 | -287 |
Total Common Shareholders' Equity | 39.84 | 30.72 | 32.63 | 115.76 | 290.83 | 399.48 |
Shareholders' Equity | 39.84 | 30.72 | 32.64 | 115.76 | 290.83 | 399.48 |
Total Liabilities & Equity | 135.03 | 140.8 | 136.21 | 177.12 | 323.56 | 472.45 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 27.08 | 29.95 | 60.42 | 27.57 | 3.98 | 6.6 |
Net Cash (Debt) | 23.7 | 51.91 | 6.5 | 83.74 | 248.8 | 395.3 |
Net Cash Growth | 7.04% | 699.06% | -92.24% | -66.34% | -37.06% | 44.23% |
Net Cash Per Share | 0.32 | 0.78 | 0.13 | 1.61 | 4.80 | 7.64 |
Book Value | 39.84 | 30.72 | 32.63 | 115.76 | 290.83 | 399.48 |
Book Value Per Share | 0.54 | 0.46 | 0.63 | 2.23 | 5.61 | 7.72 |
Tangible Book Value | -7.02 | -16.14 | -14.23 | 68.9 | 243.97 | 356.82 |
Tangible Book Value Per Share | -0.10 | -0.24 | -0.27 | 1.33 | 4.71 | 6.90 |